Home Hydroponics Market Size, Share & Trends Analysis Report (2025–2030)
Home Hydroponics Market by Product Type (Hydroponic Growing Systems and Components), System Type (Aggregate Systems and Liquid Systems), Crop Seed Type (Leafy Greens & Herbs and Fruits & Vegetables), and Region - Global Forecast to 2030
The home hydroponics market is estimated at USD 1.80 billion in 2025 and is projected to reach USD 3.77 billion by 2030, at a CAGR of 16.0% from 2025 to 2030. Environmental, technological, and lifestyle factors are driving the home hydroponics market. Increasing awareness about sustainable and pesticide-free food production has led consumers to explore alternative growing methods that reduce resource use and carbon footprint. Urbanization and limited availability of gardening space in cities are pushing households toward compact, soil-less farming systems. Technological innovations such as automated nutrient delivery, IoT-based monitoring, and energy-efficient LED lighting have made hydroponics more user-friendly and accessible.
Home Hydroponics Market Growth Drivers
Urbanization & Space Constraints: As more people move to cities, limited gardening space has made compact, soil-less systems appealing for urban dwellers.
Sustainability & Food Security: Growing concerns about food quality, pesticide use, and supply chain disruptions have increased interest in home-grown, chemical-free produce.
Technological Advancements: Innovations such as automated nutrient delivery, IoT-based monitoring, and energy-efficient LED lighting have made hydroponics more accessible and user-friendly for beginners and enthusiasts alike.
Health & Lifestyle Trends: Rising health awareness and a preference for fresh, homegrown food are spurring adoption, especially among younger, tech-savvy consumers.
Home Hydroponics Market Trends
Smart Hydroponic Systems: Integration of IoT, automation, and app-based controls allows users to monitor and manage plant growth remotely, simplifying care and optimizing yields.
Compact & Modular Kits: Designed for small spaces, these kits are popular among apartment dwellers and beginners.
Sustainable Living: Eco-conscious consumers are drawn to hydroponics for its efficient water use, reduced carbon footprint, and minimal reliance on pesticides.
By system type, the nutrient film technique segment holds a significant share in the home hydroponics market
The nutrient film technique (NFT) holds a significant share in the system type segment of the home hydroponics market due to its efficiency, simplicity, and suitability for small-scale indoor setups. NFT systems work by flowing a thin film of nutrient-rich water over the roots of plants, providing constant access to oxygen and nutrients while minimizing water usage. This method is particularly popular among home growers for leafy greens and herbs, as it supports rapid growth and is relatively easy to maintain.
The compact and modular design of NFT systems makes them ideal for urban households with limited space, and their low operational cost further enhances their appeal. The rising availability of affordable NFT kits and DIY-friendly designs has also contributed to widespread adoption. As consumers become more environmentally conscious and seek cost-effective solutions for growing fresh produce at home, the NFT system continues to gain traction as a preferred choice in the hydroponics market.
By crop seed type, the leafy greens & herbs segment holds a significant share in the home hydroponics market
Leafy greens and herbs hold the largest share in the home hydroponics market due to their fast growth cycles, compact root structures, and suitability for indoor environments. Lettuce, spinach, kale, basil, mint, and parsley thrive in hydroponic systems and require minimal space and maintenance, making them ideal for home growers. These crops can be harvested frequently and regrown quickly, offering a steady, fresh supply for personal consumption. Their high nutritional value and widespread culinary use further increase their appeal among health-conscious consumers. Additionally, leafy greens and herbs are less sensitive to variations in climate and lighting conditions compared to fruiting plants, making them more compatible with small-scale, beginner-friendly hydroponic setups.
Asia Pacific dominates the home hydroponics market share.
The Asia Pacific region holds a significant share in the home hydroponics market, driven by rapid urbanization, rising population density, and growing concerns over food security and environmental sustainability. China, Japan, South Korea, and Singapore are at the forefront of adopting innovative indoor farming technologies due to limited arable land and increasing demand for fresh, pesticide-free produce.
The rising middle class in these nations, along with a strong cultural emphasis on healthy living and homegrown food, fosters widespread acceptance of hydroponic systems. Urban consumers, particularly in densely populated cities, are turning to compact and modular home hydroponics as a practical solution for space constraints and food quality concerns. Additionally, the increasing use of technology in everyday life across the region has paved the way for smart, app-controlled hydroponic kits to gain popularity among tech-savvy households.
Government initiatives and supportive policies further reinforce Asia Pacific's strong position in the home hydroponics market. For example, Singapore's '30 by 30' initiative aims to produce 30% of the nation's nutritional needs locally by 2030, encouraging urban farming methods such as hydroponics. Similarly, investments in smart agriculture, sustainability education, and public awareness campaigns in India and China are boosting market potential. The presence of regional startups and growing partnerships between agritech companies and urban housing developers are also expanding product availability. With a blend of economic growth, rising health awareness, and policy support, the Asia Pacific region is poised to continue its influential role in shaping the global home hydroponics landscape.
The report profiles key players such as The Scotts Company LLC (US), Hydrofarm (US), GrowGeneration Corp. (US), Rise Gardens (US), Gardyn (US), Growgreen Limited (Hong Kong), Ingarden GmbH (Germany), Holland Horticulture (UK), CLICK & GROW LLC (Estonia), and Altifarm Enverde (US).
In June 2025, GrowGeneration Corp. acquired Viagrow, a domestic supplier of gardening and hydroponic equipment.
In November 2023, Click & Grow partnered with Urban Cultivator to scale up the cultivation of its plant pods for commercial use.
In January 2023, Rise Gardens launched a new top-of-the-line, fully modular garden at CES 2023.
In October 2022, Gardyn launched Gardyn Home 3.0, its most advanced home hydroponic system.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=189262012
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Redwire Launches New Venture Company, SpaceMD, to Commercialize Pharmaceutical Development in Space; Signs Trailblazing Royalty Agreement with ExesaLibero Pharma
Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that it has formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit that will be used on Earth to create new and reformulated pharmaceuticals. SpaceMD will take advantage of the unique microgravity environment in space through the use of Redwire's innovative and flight-proven Pharmaceutical In-Space Laboratory (PIL-BOX) technology to grow the seed crystals. 28 PIL-BOX systems have already flown in space and have successfully crystalized 17 compounds on the ISS, including insulin and other critical molecules. SpaceMD will sell or license these seed crystals to companies that can use them to create reformulated versions of existing drugs or entirely new therapeutics. As part of this launch, SpaceMD announced a trailblazing licensing agreement with ExesaLibero Pharma, Inc., an innovative pharmaceutical company developing new small molecule drugs to treat bone disease. Under the terms of the agreement, ExesaLibero Pharma will work with SpaceMD to advance and enhance its groundbreaking small-molecule drug ELP-004 and other relevant compounds via the PIL-BOX system. This drug could hold the key to controlling the insidious bone erosion that numerous debilitating diseases cause, such as rheumatoid arthritis, multiple myeloma, diabetes, periodontal disease, and tuberculosis. The results of these microgravity investigations will inform ExesaLibero Pharma's Investigative New Drug (IND) application to the Food and Drug Agency (FDA). Following the approval of the IND by the FDA, ExesaLibero Pharma expects to initiate clinical trials that will lead to full approval of the drug for clinical use. Through this first-of-its-kind agreement, SpaceMD will receive royalties from any commercial sales of resulting pharmaceutical products. 'Redwire is excited to announce the formation of SpaceMD. This new entity represents the evolution of our PIL-BOXstrategy, moving from experimentation to full commercialization with significant upstream revenue potential,' said Peter Cannito, Chairman and CEO of Redwire. 'This agreement with ExesaLibero Pharma signals a revolutionary paradigm shift for commercial utilization of microgravity. Redwire and now SpaceMD are translating the benefits of microgravity research into product value for pharmaceutical companies with the goal of transforming the future of therapeutics and creating value for our stakeholders.' 'We have seen firsthand how the microgravity environment can be a game-changer for drug development, and we look forward to expanding our work with SpaceMD through this exciting collaboration,' said John Barnett, Ph.D., President and Chief Scientific Officer at ExesaLibero. 'This collaboration will help us continue to advance our drug development and discovery process and lead to better outcomes for patients and future astronauts.' Redwire is a global leader in microgravity research and development technologies, having flown hundreds of experiments on both the Space Shuttle and the ISS. Redwire currently has eleven research and manufacturing facilities on the ISS, more than any other company in the world. Redwire's microgravity technology enables space biotechnology and pharmaceutical development, helping customers reach a commercial market and paving the way for microgravity research on future commercial space stations. Previous investigations conducted by Redwire have been with partners such as Bristol Myers Squibb, Eli Lilly and Company, and Butler University. These efforts focused on unlocking insights to improve treatments for cardiovascular disease, obesity, and diabetes. About Redwire Redwire Corporation (NYSE:RDW) is an integrated space and defense tech company focused on advanced technologies. We are building the future of aerospace infrastructure, autonomous systems and multi-domain operations leveraging digital engineering and AI automation. Redwire's approximately 1,300 employees located throughout the United States and Europe are committed to delivering innovative space and airborne platforms transforming the future of multi-domain operations. For more information, please visit SpaceMD is a subsidiary of Redwire Corporation focused on leveraging the microgravity environment of space to create new advances in pharmaceuticals, biotech, and other fields. SpaceMD utilizes innovative, flight-proven Redwire hardware to conduct this potentially life-enhancing work. SpaceMD uses the unique nature of space to benefit life on Earth.
Globe and Mail
2 hours ago
- Globe and Mail
Is Costco Stock Still the Safest Bet? Data Backs the Defensive Case
At a time when volatility continues to haunt, Costco Wholesale Corporation COST remains a poster child for defensive investing. The company's unique membership-based model and pricing discipline have solidified its position as a resilient force in the retail space. A key indicator of this strength is the 90.2% global membership renewal rate, alongside a 5.2% increase in worldwide shopping traffic during the third quarter of fiscal 2025. Membership revenues continue to be a key pillar for Costco. In the third quarter, income from membership fees increased 10.4% year over year, providing a steady revenue stream in a volatile environment. Paid memberships grew 6.8% to 79.6 million, with renewal rates remaining steady at 92.7% in the United States and Canada. Executive memberships, which now account for 73.1% of total sales, demonstrate member loyalty. Costco's operational agility further bolsters its defensive profile. The company has effectively navigated tariff disruptions and supply-chain constraints by rerouting goods and sourcing more from local suppliers. This flexibility helps contain cost pressures and allows it to offer the best possible prices. For example, by manufacturing or procuring Kirkland Signature items within the countries where they are sold, Costco has reduced shipping expenses and improved price consistency. Kirkland Signature continues to gain traction, with its sales outpacing overall company growth and penetration up 50 basis points year over year. Additionally, initiatives like the 'Buy Now, Pay Later' option and e-commerce expansion reflect Costco's forward-thinking approach, strengthening its defensive appeal in an evolving retail landscape. Costco's Price Performance, Valuation and Estimates Costco, which competes with Dollar General Corporation DG and Target Corporation TGT, has been a standout performer, with shares rallying 18.8% in the past year, outpacing the industry 's growth of 11.9%. Shares of Dollar General and Target have declined 11.7% and 25.5%, respectively, in the aforementioned period. From a valuation standpoint, Costco's forward 12-month price-to-earnings ratio stands at 48.15, higher than the industry's ratio of 31.77. COST carries a Value Score of D. Costco is trading at a premium to Target (with a forward 12-month P/E ratio of 12.70) and Dollar General (17.85). The Zacks Consensus Estimate for Costco's current financial-year sales and earnings per share implies year-over-year growth of 8.1% and 11.6%, respectively. Costco currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Target Corporation (TGT): Free Stock Analysis Report Dollar General Corporation (DG): Free Stock Analysis Report
Globe and Mail
3 hours ago
- Globe and Mail
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
Johnson & Johnson JNJ announced strong second-quarter results earlier this month. The drug and medical device giant beat estimates for both earnings and sales. Despite the loss of exclusivity ('LOE') of its blockbuster drug, Stelara, its Innovative Medicine unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. The new drugs also contributed significantly to sales. Importantly, its MedTech sales improved from first-quarter levels, driven by strong momentum in Cardiovascular, Surgery and Vision segments despite continued headwinds in China. But what caught investor attention is the fact that J&J raised its sales expectations for 2025 by around $2.0 billion at the mid-point to reflect a strong operational performance in the first half, coupled with currency tailwinds. The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90, driven by top-line strength, the favorable impact of foreign currency and lowered tariff impact. J&J halved its expectations for tariff-related costs this year from $400 million to $200 million. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. Newly launched products should drive better growth in the Innovative Medicine segment in the second half despite the impact of Stelara LOE and Medicare Part D redesign. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications, including Tremfya in inflammatory bowel disease indications and Rybrevant in non-small cell lung cancer. In the MedTech segment, the increased adoption of newly launched products in Cardiovascular, Surgery and Vision is likely to drive growth. However, China will continue to be a headwind in 2025. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025. We believe that J&J should be able to maintain the strong momentum of the first half in the second half. In fact, J&J expects growth to accelerate from 2026. ABBV & BMY Also Raise Guidance Other drugmakers that also raised their financial outlook for the year, along with their second-quarter results, are AbbVie ABBV and Bristol-Myers BMY. ABBV raised its full-year 2025 EPS guidance to $11.88-$12.08, up from its prior $11.67-$11.87 range.' Bristol-Myers raised its annual revenue guidance to $46.5-$47.5 billion from $45.8-$46.8 billion. BMY, however, cut its EPS outlook due to IPRD charges related to its recent deal with BioNTech BNTX for the global co-development and co-commercialization of BNTX's investigational bispecific antibody BNT327 across numerous solid tumor types. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 17.6% in the year-to-date period against a 3.3% decrease of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company's shares currently trade at 15.0 forward earnings, slightly higher than 14.29 for the industry. The stock is, however, trading below its five-year mean of 15.68. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $10.62 per share to $10.86 over the past 30 days, while that for 2026 has risen from $11.0 to $11.36 over the same timeframe. Image Source: Zacks Investment Research J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
